AMA PRA Category 1 Credit™ modules, clinical case studies, and professional development resources for healthcare providers in cannabis medicine.
AMA PRA Category 1 Credits 12,000+ clinician learners Updated quarterly
CME Modules
8.0 total credits available
Most Popular
PharmacologyIntermediate
Cannabinoid Pharmacology for Clinicians
Comprehensive review of CB1/CB2 receptor pharmacology, endocannabinoid system physiology, THC and CBD mechanisms of action, and clinically relevant pharmacokinetics including bioavailability by route and drug interactions.
Learning Objectives
Describe the endocannabinoid system and its role in homeostasis
Explain the pharmacological differences between THC and CBD
Evidence-based review of cannabinoids for neuropathic pain, cancer pain, and musculoskeletal pain. Covers patient selection, dosing protocols, monitoring, and integration with existing pain management strategies.
Learning Objectives
Evaluate the evidence base for cannabinoids in neuropathic and cancer pain
Apply evidence-based dosing frameworks for pain management
Identify appropriate patient candidates and contraindications
Monitor for adverse effects and therapeutic response
In-depth review of Epidiolex clinical trial data, anticonvulsant mechanisms, drug interactions with antiepileptic drugs, and practical prescribing guidance for Dravet and Lennox-Gastaut syndromes.
Learning Objectives
Summarize Phase 3 RCT evidence for CBD in Dravet and Lennox-Gastaut syndromes
Manage the clobazam-CBD interaction in clinical practice
Monitor liver function in patients on Epidiolex
Counsel patients and families on realistic expectations
Medical Cannabis: Legal, Ethical, and Documentation Considerations
Practical guidance on state medical cannabis programs, documentation requirements, informed consent, liability considerations, and ethical obligations when patients ask about cannabis.
Learning Objectives
Navigate state medical cannabis certification requirements
Document cannabis discussions and recommendations appropriately
Apply informed consent principles to cannabis recommendations
Understand liability considerations and professional standards
Evidence-based review of cannabinoids for CINV, cancer pain, and cancer cachexia. Addresses the anti-tumor evidence gap and how to counsel patients who ask about cannabis as a cancer treatment.
Learning Objectives
Apply FDA-approved cannabinoid antiemetics appropriately in CINV
Evaluate nabiximols evidence for opioid-refractory cancer pain
Counsel patients accurately about anti-tumor claims vs. palliative evidence
Integrate cannabinoids into comprehensive oncology supportive care
Real-world clinical scenarios with expert commentary. Each case includes patient presentation, evidence review, clinical decision framework, and teaching points.
Pain Medicine
Case: 58-Year-Old with Refractory Neuropathic Pain
A 58-year-old woman with diabetic peripheral neuropathy has failed gabapentin (3,600mg/day), duloxetine (120mg/day), and amitriptyline (75mg/day). She asks about medical cannabis. How do you approach this?
A 9-year-old with genetically confirmed Dravet syndrome has 15–20 convulsive seizures/month despite valproate and clobazam. Parents ask about Epidiolex. What do you tell them, and how do you manage the drug interactions?
A 34-year-old veteran with PTSD reports using cannabis nightly for sleep and nightmares. He wants your support for a medical cannabis card. How do you evaluate this, and what are the evidence-based alternatives?
A 72-year-old on warfarin for atrial fibrillation presents with an INR of 6.8. On further questioning, she started taking a CBD oil supplement 3 weeks ago. How do you manage this, and what do you tell her going forward?
